Slow Churn Higher Or Another Pause For BLCM?"Since August 21st, Bellicum’s stock has made a very strong rally on the back of news releases. The price of the biotech penny stock is up nearly over 30% since the beginning of the month. This gain and volume increase came initially following the company’s $140 million public offering on the 21st. Bellicum is also participating in 3 healthcare investor conferences throughout September."
Source: A List Of Penny Stocks To Watch As They Approach September Highs
pennystocks.com
And I understand how speculation could play a role. However, there's less volume now compared to a few weeks ago and it's approaching a level that also falls in line with previous levels it was at before.
Biotechnology
AVEO Fake Out? Or Consolidation Before Another Breakout?Aveo recently announced that the Tivozanib drug , in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September 10. Good Phase 3 news? Seemingly so but will profit taking crush the hopes of this breaking beyond $1 for good?
Chart indicates possible technical levels and it seems that around today's high is one of those levels.
"Biopharmaceutical company, Aveo Pharmaceuticals Inc. ( AVEO ) is pursuing treatment plans for different tumors. The company has 4 treatment plans in clinical trials and 2 additional ones undergoing pre-trials. Aveo’s lead product, Tivozanib, has completed the clinical trials and has been filed and marketed."
Source: A List Of Penny Stocks To Watch As They Approach September Highs
Biotech Legendary Investor Alex Vieira Nails Acadia 400% Rally!Indeed! Strong Buy since $13.7 made public worldwide
ARDELYX INC - NASDAQ: $ARDX - Constructive ConsolidationAfter breaking to higher ground a week ago on enormous volume, shares of ARDELYX INC - NASDAQ: ARDX find themselves in constructive consolidation mode digesting the recent run on lower volume as we can observe from the Daily chart above.
With the stock trading well above its 20/50 and 200 DMA's on the Daily timeframe, the short-term technical posture of ARDX remains favorable. While the stock may require additional consolidation in order to absorb its recent sharp move and allow itself to build cause/energy before its next attempt at loftier levels, ARDX continues to shape-up technically.
Moving forward, both investors/traders may want to continue to closely monitor the action in ARDX as we suspect that after its current period of consolidation resolves, we may just witness another move into northern territory with and initial objective of $8 and the potential for a secondary objective in the $11-$15 range down the road.
Thus, investors/traders may want to put ARDX front-and-center on their radars.
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..."
3 Penny Stocks Making New Highs In September
NASDAQ:MRNS
ABEO Stock To Watch (But For How Long?)ABEO stock has been beaten down for much of 2019. It had declined by as much as 80% since the beginning of the year. It went on to emerge as one of the biggest gainers in the market yesterday. The company announced that it was going to explore options that could unlock value for the shareholders. It stated that even an outright sale or a takeover is being considered. However, volume has been cut down dramatically on Wednesday compared to Tuesday's volume. How long can the run sustain and what will come of ABEO later this month?
3 Penny Stocks Making New Highs In September
NASDAQ:ABEO
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move?
"Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61."
Original Article: 4 Penny Stocks To Watch Under $4
NASDAQ:NTEC
Autonomous AI Robotic Trading Decimates Mallinckrodt Share PriceMallinckrodt named the best biotech stocks to sell short in a decade
1W) Biotech's RollercoasterWill have a serious drop soon.
But it's all the set up for the bullish BAT pattern guys.
Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here .
Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float.
Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame.
Follow me on twitter and instagram @ #VolatilityWatch
Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.
Davita - now a BULL trend Technicals analysis WEEKLY
Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull)
50SMA is now crossing above the 200SMA. (Bull)
OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June.
Headlines / Fundamental
On July 10th:
President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics.
Analyst fair value target price is $79. Meaning 38% undervalued .
CODX buy NOW around 1.1usd - PUMP and DUMP - go to the MOONBUY CODX = 1.1$
STOP=0.7$
TARGET1=2.9$ R=4
TARGET2=3.8$ R=7
TARGET3=5.1$ R=10
Chart 1 month big big level and base = 0.8$ to 1.1$
NEXT level 3.0$ usd
CODX is setting up to be a major player in the extremely “Profitable” $100Bil Biotechnology sector focusing on “Cancer Detection” using its patented CoPrimer™ technology with applications in Liquid Biopsy and companion diagnostic tests.
CODX just announced exciting news of favorable results on a study to detect cancer mutations using its patented CoPrimer™ technology, with applications in liquid biopsy and companion diagnostic tests.
Co-Diagnostics Disrupting Multi-Billion Dollar Biotech Sector With State-Of-The-Art Patented CoPrimers Providing High-Performance Detection of Cancer Mutations in Liquid Biopsy Samples Co-Diagnostics Inc. looks to be moving forward in a record-breaking pace...
I believe at just $1.10 this NASDAQ biotech stock is seriously undervalued.
Look at one of CODX biggest rivals biotech Giant Illumina it trades at $286 dollars per share, another rival to look at is Myriad Genetics it trades at $25 dollars per share.
One of CODX biggest rivals is likely biotech giant Illumina which is a “Cancer Detection Stock.” Illumina trades at $286 dollars per share, and drew over $100Mil from Bill Gates, Jeff Bezos and others to launch Grail.
CODX buy NOW around 1.1usd - PUMP and DUMP - go to the MOON
G1 Therapeutics RALLYEarnings/News
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
Extended Parabola #VolatilitywatchKRYS has hit FIB golden ratio resistance and peaked out on 5th wave. Looking for pullback to low $40's then we'll find out if it wants to fill the gap.
Please like/ comment so I can continue looking for awesome trades. Thank you in advance.
Message me if your interested in learning more on pattern analysis . Follow trend, Buy low sell high!!
Follow me on Instagram or Twitter @VolatilityWatch
Disclosure: I am not a financial advisor. This is not a note to buy or sell. Please do your homework before investing
#IMMU look at Risk vs. Reward #VolatilitywatchThis trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line.
From current stock price, potential risk/reward around 3.5 : 1
downside risk: $1.39
upside reward: $3.50-$5
Recent selloff after earnings showed strong support at the $11.59 level, which also made a double bottom.
This selloff started around July, 2018. to emphasize the double bottom even more, the pullback from peak to trough retraced .618; a key level of Fibonacci support.
MACD indicator showing strong convergence with price
Price above 20 day moving average.
5-day exponential moving average above 20 day moving average, indicating strength in trend.
Conclusion: $IMMU seems to bring opportunistic risk/ reward to investors who are sidelined. Double bottoms are significant patterns when looking for price reversal.
Tip # 11: Some investors wait to buy until after stock price crosses above moving averages such as the 20, 50, 100, and 200 day. These are key phycological levels to watch when trading and investing.
Like and follow so I can continue giving trend analysis and trade ideas. Thank you in advance =)
Follow me on twitter or Instagram @Volatilitywatch
Disclosure: I do not own IMMU. This is not a note to buy or sell. Please do your homework before investing.
Cala #VolatilityWatchAfter a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be in the midst of a new uptrend.
June 2019 selloff marked double bottom for CALA.
This looks to be very attractive from risk vs reward standpoint (Assuming markets stay strong, I see approximately $0.40 downside vs $1.50 upside).
Extrapolating previous price patterns (shown in chart) Cala looks to be in the midst of 2nd wave (Bullish corrective wave).
the projection is based off previous price patterns where CALA retraced approximately .618 and extended above the 1.618 Fibonacci extension level.
trend indicators also signaling uptrend in play (see chart).
Tip # 9: Stop losses are a good way to get you out of a trade that you don't want to be in. But remember, they only work during market hours.
Please Like and Follow so I can continue giving trade ideas and build up my reputation. Thank you in advance =)
Have a Instagram or Twitter? follow me @VolatilityWatch
Disclosure : I do not own a position in Cala. I may buy/ sell within the next 72 hours. This is not a note to buy or sell. Please do your own homework before investing.
PhaseBio technical studyThere is a strong support area around $9.5 - $10.5
Could be a good opportunity if it keeps respecting the limits.
Technical data
RSI @42 (waiting for this indicator to go higher)
OBV reaching for higher highs
Bollinger bandwith relatively high.
Not buying yet, but it's worth it to keep on your watchlist.
Biotech Sector bullish channelThere is a good RRR to enter XBI today. We seem to be in a bullish channel (showed in chart).
IMMU - Which is 1.5% of the sector, is also a good option. (higher risk - higher reward).
MARKER THERAPEUTICS INC - NASDAQ: $MRKR ConsolidatesAfter recapturing its 200 DMA a week ago on meaningful volume, the shares of MARKER THERAPEUTICS INC - NASDAQ;MRKR have found themselves consolidating the recent move in a constructive and orderly manner as is evidenced in the Daily chart above.
With the stock now trading above all of its important moving averages 20/50/200 DMA's, the technical posture is favorable for MRKR .
In addition, there are potential catalysts for the stock forthcoming in the weeks ahead, in particular, Marker Therapeutics is to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma on July 20, 2019.
finance.yahoo.com
Thus, moving forward, both investors/traders may want to continue to monitor the action closely and should MRKR be capable of going topside of the $8.15 figure at any point in the days ahead, we suspect that the stock may just have eyes for the $9 - $10 zone once the present consolidation runs its course.
CYTOKINETICS INC - NASDAQ: $CYTK Grinding HigherAfter recapturing its 200 DMA in early Spring (March), shares of CYTOKINETICS INC - NASDAQ;CYTK have been grinding into higher ground as we can observe in the Daily chart above.
Additionally, CYTK continues to trade above all of its important moving averages 20/50/200 DMA's, suggestive of a favorable technical posture.
Furthermore, when extending out to both the Weekly and Monthly time-frames, CYTK remains in relatively good shape, thus, we have a stock that displays encouraging technical's across multiple time-frames.
Moving forward, both investors/traders may want to continue to monitor the action closely, particularly, should CYTK be capable of going topside of the $11.50 figure and perhaps of more importance the $11.95 level, such development would likely trigger its next advance into a primary objective of $13 with a secondary objective in the $16 handle.
Thus, investors/traders may want to put CYTK front-and-center on their radars and pay close attention to the levels mentioned above for additional clues/evidence that CYTK is ready to embark on its next major leg.
Biogen - opportunity to get in at the bottomAfter a recent downward gap, BIIB looks to me to have established a new upward channel. With bullish MACD, great analyst ratings, a history of earnings beats, and the next earnings coming up in mid-July, BIIB should be up in the short-to-medium term. Set fairly tight stops to protect against a downward channel breakout.
Here's my Biogen trading plan Monday morning:
Limit buy 238.17
Stop Loss: 231
Take profit: 287
